MA42592A - Utilisation de dérivés de 2-(pyrazolopyridin-3-yl) pyrimidine en tant qu'inhibiteurs de jak - Google Patents

Utilisation de dérivés de 2-(pyrazolopyridin-3-yl) pyrimidine en tant qu'inhibiteurs de jak

Info

Publication number: MA42592A
Authority: MA; Morocco
Prior art keywords: pyrazolopyridin; pyrimidine derivatives; jak inhibitors; jak; inhibitors
Prior art date: 2015-06-11

Application number

MA042592A

Other languages

English (en)

Inventor

Trias Cristina Esteve

Rodriguez Jacob Gonzalez

Moll Joan Taltavull

Juan Bernat Vidal

Original Assignee

Almirall Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-06-11

Filing date

2016-06-10

Publication date

2018-06-20

2016-06-10 Application filed by Almirall Sa filed Critical Almirall Sa

2018-06-20 Publication of MA42592A publication Critical patent/MA42592A/fr

Links

PWNLEGTUORZMTM-UHFFFAOYSA-N 3-pyrimidin-2-yl-1h-pyrazolo[4,3-b]pyridine Chemical class N1=CC=CN=C1C1=NNC2=CC=CN=C12 PWNLEGTUORZMTM-UHFFFAOYSA-N 0.000 title 1
229940122245 Janus kinase inhibitor Drugs 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Pulmonology (AREA)
Immunology (AREA)
Hematology (AREA)
Dermatology (AREA)
Neurology (AREA)
Ophthalmology & Optometry (AREA)
Epidemiology (AREA)
Obesity (AREA)
Neurosurgery (AREA)
Oncology (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Endocrinology (AREA)
Biomedical Technology (AREA)
Emergency Medicine (AREA)
Virology (AREA)
Heart & Thoracic Surgery (AREA)
Pain & Pain Management (AREA)
Cardiology (AREA)
Otolaryngology (AREA)
Communicable Diseases (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

MA042592A 2015-06-11 2016-06-10 Utilisation de dérivés de 2-(pyrazolopyridin-3-yl) pyrimidine en tant qu'inhibiteurs de jak MA42592A (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP15382305		2015-06-11

Publications (1)

Publication Number	Publication Date
MA42592A true MA42592A (fr)	2018-06-20

Family

ID=53476802

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA042592A MA42592A (fr)	2015-06-11	2016-06-10	Utilisation de dérivés de 2-(pyrazolopyridin-3-yl) pyrimidine en tant qu'inhibiteurs de jak

Country Status (22)

Country	Link
US (1)	US10759793B2 (fr)
EP (1)	EP3307272A1 (fr)
JP (1)	JP2018516954A (fr)
KR (1)	KR20180012854A (fr)
CN (1)	CN107667106A (fr)
AR (1)	AR104963A1 (fr)
AU (1)	AU2016275716C1 (fr)
BR (1)	BR112017025781A2 (fr)
CA (1)	CA2987328A1 (fr)
CL (1)	CL2017003107A1 (fr)
CO (1)	CO2017011996A2 (fr)
CR (1)	CR20170557A (fr)
EA (1)	EA035312B1 (fr)
HK (1)	HK1246667A1 (fr)
IL (1)	IL255668A (fr)
MA (1)	MA42592A (fr)
MX (1)	MX2017015029A (fr)
PE (1)	PE20180279A1 (fr)
PH (1)	PH12017502236A1 (fr)
SG (1)	SG10201911926UA (fr)
TW (1)	TW201705961A (fr)
WO (1)	WO2016198663A1 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES3053874T3 (en)	2015-08-24	2026-01-27	Glaxosmithkline Ip No 2 Ltd	Biopharmaceutical compositions
BR112018016300A2 (pt) *	2016-02-12	2018-12-26	Univ Zuerich	fumarato de dimetila (dmf) para prevenção ou tratamento de gota, acne, diabetes, vitiligo e/ou pioderma gangrenoso
WO2017189805A1 (fr)	2016-04-27	2017-11-02	Abbvie Inc.	Méthodes de traitement de maladies dans lesquelles l'activité de l'il-13 est préjudiciable à l'aide d'anticorps anti-il-13
JP7071383B2 (ja) *	2016-11-08	2022-05-18	キャンサー・リサーチ・テクノロジー・リミテッド	ｃｄｃ７阻害剤としてのピリミジノン誘導体
US20180235931A1 (en) *	2017-01-17	2018-08-23	Menlo Therapeutics Inc.	Use of neurokinin-1 antagonists as antitussives
TW201834649A (zh) *	2017-03-02	2018-10-01	新加坡商亞獅康私人有限公司	癌症療法
US11311548B2 (en)	2017-03-02	2022-04-26	Aslan Pharmaceuticals Pte. Ltd.	Cancer therapy
US11957931B2 (en) *	2017-04-26	2024-04-16	Yale University	Compositions and methods for treating vitiligo
CN108514637A (zh) *	2018-05-07	2018-09-11	山东省眼科研究所	Stat3抑制剂s31-201在治疗干眼症中的应用
CN109810991B (zh) *	2019-03-02	2021-11-12	昆明理工大学	二氢蝶酸合酶基因folP的用途
BR112022019387A2 (pt) *	2020-03-27	2022-11-16	Dong A St Co Ltd	Derivados de aminopirimidina e seu uso como moduladores de receptores de aril hidrocarbonetos
MX2022014901A (es) *	2020-06-02	2023-01-18	Nerre Therapeutics Ltd	Antagonistas del receptor de neuroquinina (nk)-1 para su uso en el tratamiento de condiciones de fibrosis pulmonar promovidas por lesion mecanica a los pulmones.
US12668594B2 (en)	2020-12-23	2026-06-30	Sudo Biosciences Limited	TYK2 inhibitors and uses thereof
CA3210150A1 (fr) *	2021-02-02	2022-08-11	Pfizer Inc.	Regime posologique pour le traitement de l'eczema de la main chronique
IL305119A (en)	2021-02-19	2023-10-01	Sudo Biosciences Ltd	Tyk2 inhibitors and uses thereof
TW202302583A (zh)	2021-02-19	2023-01-16	英商蘇多生物科學有限公司	Ｔｙｋ２抑制劑及其用途
KR20230159421A (ko)	2021-02-19	2023-11-21	수도 바이오사이언시즈 리미티드	Tyk2 억제제 및 이의 용도
AU2022270072A1 (en) *	2021-05-03	2023-11-02	Incyte Corporation	Jak1 pathway inhibitors for the treatment of prurigo nodularis
KR20240027044A (ko) *	2021-07-30	2024-02-29	일라이 릴리 앤드 캄파니	바리시티닙을 사용한 손 습진의 치료
US12642802B2 (en)	2021-12-03	2026-06-02	Incyte Corporation	Topical formulations of ruxolitinib with an organic amine pH adjusting agent for treatment of skin diseases
JP2025513444A (ja) *	2022-04-21	2025-04-24	アスランファーマシューティカルズピーティーイーリミテッド	自己免疫性皮膚疾患の治療
WO2025095039A1 (fr) *	2023-10-31	2025-05-08	ティア・リサーチ・コンサルティング合同会社	Composition pharmaceutique pour maladies de la peau et procédé de recherche d'une nouvelle utilisation de médicament
CN119707992B (zh) *	2024-12-20	2025-12-09	杭州同舟生物技术有限公司	一种纳呋拉啡人工半抗原、人工抗原及其制备方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS54128591A (en)	1978-03-25	1979-10-05	Kyowa Hakko Kogyo Co Ltd	Cephalosporin analog
EP2338888A1 (fr)	2009-12-24	2011-06-29	Almirall, S.A.	Dérivés d'imidazopyridine en tant qu'inhibiteurs JAK
UY33213A (es) *	2010-02-18	2011-09-30	Almirall Sa	Derivados de pirazol como inhibidores de jak
EP2397482A1 (fr)	2010-06-15	2011-12-21	Almirall, S.A.	Dérivés d'imidazolone d'hétéroaryle en tant qu'inhibiteurs de JAK
AR086042A1 (es) *	2011-04-28	2013-11-13	Galapagos Nv	Compuesto util para el tratamiento de enfermedades degenerativas e inflamatorias y composicion farmaceutica
WO2013025628A1 (fr) *	2011-08-15	2013-02-21	Ligand Pharmaceuticals Incorporated	Composés et procédés d'inhibition de janus kinase
AU2012312303B2 (en) *	2011-09-22	2016-09-15	Merck Sharp & Dohme Corp.	Cyanomethylpyrazole carboxamides as janus kinase inhibitors
TW201605811A (zh) *	2013-12-11	2016-02-16	阿爾米雷爾有限公司	作為jak抑制劑之吡唑并嘧啶-2基衍生物

2016
- 2016-06-08 TW TW105118168A patent/TW201705961A/zh unknown
- 2016-06-10 CR CR20170557A patent/CR20170557A/es unknown
- 2016-06-10 EA EA201792689A patent/EA035312B1/ru not_active IP Right Cessation
- 2016-06-10 CA CA2987328A patent/CA2987328A1/fr not_active Abandoned
- 2016-06-10 MA MA042592A patent/MA42592A/fr unknown
- 2016-06-10 CN CN201680030333.6A patent/CN107667106A/zh active Pending
- 2016-06-10 AU AU2016275716A patent/AU2016275716C1/en not_active Ceased
- 2016-06-10 SG SG10201911926UA patent/SG10201911926UA/en unknown
- 2016-06-10 JP JP2017563955A patent/JP2018516954A/ja active Pending
- 2016-06-10 WO PCT/EP2016/063391 patent/WO2016198663A1/fr not_active Ceased
- 2016-06-10 EP EP16728326.6A patent/EP3307272A1/fr not_active Withdrawn
- 2016-06-10 KR KR1020187000866A patent/KR20180012854A/ko not_active Withdrawn
- 2016-06-10 MX MX2017015029A patent/MX2017015029A/es unknown
- 2016-06-10 BR BR112017025781-5A patent/BR112017025781A2/pt not_active Application Discontinuation
- 2016-06-10 US US15/735,235 patent/US10759793B2/en not_active Expired - Fee Related
- 2016-06-10 AR ARP160101733A patent/AR104963A1/es unknown
- 2016-06-10 HK HK18106235.2A patent/HK1246667A1/zh unknown
- 2016-06-10 PE PE2017002479A patent/PE20180279A1/es unknown
2017
- 2017-11-14 IL IL255668A patent/IL255668A/en unknown
- 2017-11-27 CO CONC2017/0011996A patent/CO2017011996A2/es unknown
- 2017-12-05 CL CL2017003107A patent/CL2017003107A1/es unknown
- 2017-12-07 PH PH12017502236A patent/PH12017502236A1/en unknown

Also Published As

Publication number	Publication date
CL2017003107A1 (es)	2018-04-02
SG10201911926UA (en)	2020-01-30
CO2017011996A2 (es)	2018-03-28
IL255668A (en)	2018-01-31
NZ737314A (en)	2021-02-26
WO2016198663A1 (fr)	2016-12-15
EA035312B1 (ru)	2020-05-27
CR20170557A (es)	2018-02-06
KR20180012854A (ko)	2018-02-06
TW201705961A (zh)	2017-02-16
MX2017015029A (es)	2018-04-13
PE20180279A1 (es)	2018-02-07
HK1246667A1 (zh)	2018-09-14
AR104963A1 (es)	2017-08-30
EA201792689A1 (ru)	2018-07-31
CN107667106A (zh)	2018-02-06
US10759793B2 (en)	2020-09-01
PH12017502236A1 (en)	2018-06-11
AU2016275716A1 (en)	2017-12-07
US20180162856A1 (en)	2018-06-14
AU2016275716C1 (en)	2020-10-15
EP3307272A1 (fr)	2018-04-18
JP2018516954A (ja)	2018-06-28
BR112017025781A2 (pt)	2018-08-14
CA2987328A1 (fr)	2016-12-15
AU2016275716B2 (en)	2020-01-23

Publication	Publication Date	Title
MA51878A (fr)	2020-12-30	Composés d'aminothiazole en tant qu'inhibiteurs de c-kit
MA40587A (fr)	2017-06-28	Composés d'aminopyrimidinyle en tant qu'inhibiteurs de jak
MA43169A (fr)	2018-09-12	Composés hétérocycliques utilisés en tant qu'inhibiteurs de pi3k-gamma
MA55194A (fr)	2022-05-04	Composés hétérocycliques en tant qu'immunomodulateurs
MA53150A (fr)	2021-05-26	Composés de benzimidazole en tant qu'inhibiteurs de c-kit
MA40774A (fr)	2017-08-08	Dérivés de diaryle-urée en tant qu'inhibiteurs de kinase p38
IL255668A (en)	2018-01-31	2-(pyrazolopyridin-3-yl)pyrimidine derivatives as jak inhibitors
MA47460A (fr)	2019-12-18	Aminotriazolopyridines utilisées en tant qu'inhibiteurs de kinase
MA42990A (fr)	2021-03-31	Composés utiles en tant qu'immunomodulateurs
MA47013A (fr)	2018-08-29	Composés benzolactames utilisés en tant qu'inhibiteurs de protéine kinase
MA51438A (fr)	2021-04-14	Composés hétérocycliques utilisés en tant qu'inhibiteurs de lsd1
MA52063A (fr)	2021-05-26	Composés de n-((hét)arylméthyl)hétéroaryle-carboxamides en tant qu'inhibiteurs de la kallicréine plasmatique
MA41140A (fr)	2017-10-17	Dérivés de 2,4-dioxo-quinazoline-6-sulfonamide en tant qu'inhibiteurs de la parg
MA42659A (fr)	2018-06-27	Dérivés hétéroaryle utilisés en tant qu'inhibiteurs de parp
DK3521282T3 (da)	2021-09-27	Quinazolinderivater anvendt til behandling af hiv
DK3692039T3 (da)	2023-03-13	Enantiomerer af substituerede thiazoler som antivirale forbindelser
EP3509581A4 (fr)	2020-04-08	Formulations de (r
MA42919A (fr)	2018-08-01	Composés bicycliques utilisés en tant qu'inhibiteurs d'atx
MA46981A (fr)	2019-10-09	Dérivés de benzimidazole en tant qu'inhibiteurs de bromodomaine
MA42918A (fr)	2018-08-01	Composés bicycliques utilisés en tant qu'inhibiteurs d'atx
MA49956A (fr)	2020-07-01	Composés de pyrimidine utilisés en tant qu'inhibiteurs de kinase jak
DK3386991T3 (da)	2020-07-13	Polycykliske forbindelser som inhibitorer af bruton's tyrosinkinase
IL252089B (en)	2020-03-31	2-amino-6-(difluoromethyl)- 5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors
EP3250035A4 (fr)	2019-02-27	Composés et leur utilisation en tant qu'inhibiteurs de bace1
EP3250367A4 (fr)	2019-01-09	Étalonnage d'agent